Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 36 (RPL21P36) is a processed pseudogene found in the human genome, related to the parent gene RPL21 that encodes a structural protein of the 60S ribosomal subunit[12][14][11][5]. Like many ribosomal protein pseudogenes, RPL21P36 is non-coding, contains disabling mutations (such as frameshifts or stop codons), and is thought to result from retrotransposition events[5]. These pseudogenes are widely distributed throughout the genome, particularly for ribosomal proteins, which are highly expressed and prone to retrotransposition[5]. There is no evidence for RPL21P36 being transcribed into a functional protein, acting as a therapeutic target, or having disease relevance or biomarker utility. Some ribosomal pseudogenes have regulatory or evolutionary significance, but no specific biological function or pathology is currently attributed to RPL21P36[12][14][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 36 (RPL21P36).